Sunitinib Malate

Licensed by Pfizer Catalog No.S1042

Sunitinib Malate Chemical Structure

Molecular Weight(MW): 532.56

Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.

Size Price Stock Quantity  
USD 97 In stock
USD 147 In stock
USD 447 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 59 Publications

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Sunitinib Malate is a multi-targeted RTK inhibitor targeting VEGFR2 (Flk-1) and PDGFRβ with IC50 of 80 nM and 2 nM in cell-free assays, and also inhibits c-Kit.
Targets
Kit [1]
(Cell-free assay)
FLT3 [1]
(Cell-free assay)
PDGFRβ [1]
(Cell-free assay)
VEGFR2 [1]
(Cell-free assay)
2 nM 80 nM
In vitro

Sunitinib also potently inhibits Kit and FLT-3. [1] Sunitinib is a potent ATP-competitive inhibitor of VEGFR2 (Flk1) and PDGFRβ with Ki of 9 nM and 8 nM, respectively, displaying >10-fold higher selectivity for VEGFR2 and PDGFR than FGFR-1, EGFR, Cdk2, Met, IGFR-1, Abl, and src. In serum-starved NIH-3T3 cells expressing VEGFR2 or PDGFRβ, Sunitinib inhibits VEGF-dependent VEGFR2 phosphorylation and PDGF-dependent PDGFRβ phosphorylation with IC50 of 10 nM and 10 nM, respectively. Sunitinib inhibits VEGF-induced proliferation of serum-starved HUVECs with IC50 of 40 nM, and inhibits PDGF-induced proliferation of NIH-3T3 cells overexpressing PDGFRβ or PDGFRα with IC50 of 39 nM and 69 nM, respectively. [2] Sunitinib inhibits phosphorylation of wild-type FLT3, FLT3-ITD, and FLT3-Asp835 with IC50 of 250 nM, 50 nM, and 30 nM, respectively. Sunitinib inhibits the proliferation of MV4;11 and OC1-AML5 cells with IC50 of 8 nM and 14 nM, respectively, and induces apoptosis in a dose-dependent manner. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
3T3 NYPIUFBrU2mwYYPlJGF{e2G7 NXT6dGp6UW6qaXLpeIlwdiCxZjDQSGdHNWmwZIXj[YQhSnKmVTDpcoNwenCxcnH0bY9vKHerdHigTWM2OCCxZjCwMlAxPyEQvF2= NIXLV|cyOjZ2NkCxPS=>
3T3 MnTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJcohq[mm2aX;uJI9nKFCuYYTlcIV1NWSncnn2[YQh\3Kxd4ToJIZi[3SxcjDpcoR2[2WmIEPUN{Bk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIECuNFEh|ryP M1uzOVEzPjR4MEG5
3T3 MUnGeY5kfGmxbjDBd5NigQ>? Mn3VTY5pcWKrdHnvckBw\iCYYYPjeYxieiCnbnTveIhmdGmjbDDndo94fGhiZnHjeI9zKHKnY3XweI9zKHerdHigTWM2OCCxZjCwMlA2KM7:TR?= NGPy[|IyOjZ2NkCxPS=>
3T3 MWjLbY5ie2ViQYPzZZk> NEL1N48zOCCvaX6= MV;EUXNQ M3nISmNmdGy3bHHyJIlvcGmkaYTpc44hd2ZiVlXHSkBqdmS3Y3XkJIh2dWGwIFvEVkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEKyJO69VQ>? NGfzRoMyPjF4MkCwPC=>
NIH3T3 NXfMTFJvU2mwYYPlJGF{e2G7 NVHXOZMzOjBibXnu M1j4WGROW09? NWjyeI1mcW6qaXLpeEBpfW2jbjDLSHIhc2mwYYPlJIV5eHKnc4Pl[EB4cXSqIFnDOVAhd2ZiMD6wNVgh|ryP NV;xSmRYOTZzNkKwNFg>
A549 M{nDTmZ2dmO2aX;uJGF{e2G7 MlzpSG1UVw>? MnrnTY5pcWKrdHnvckBw\iClLV3leEBl\XCnbnTlcpQhUEeILXnu[JVk\WRiaIXtZY4hSTV2OTDj[YxtKG2rZ4LheIlwdiC5aYToJGlEPTBib3[gNkDPxE1? NFjqTlgyQDR|NEG0OS=>
DU145 MYTGeY5kfGmxbjDBd5NigQ>? MoezSG1UVw>? NXrqWZdyUW6qaXLpeIlwdiCxZjDjMW1mfCCmZYDlcoRmdnRiSFfGMYlv\HWlZXSgbJVu[W5iRGWxOFUh[2WubDDzZ4F1fGW{aX7nJJdqfGhiSVO1NEBw\iBzMDFOwG0> NWLDe2hDOTh2M{SxOFU>
KB3-1 M1jHPWN6fG:2b4jpZ{BCe3OjeR?= MVW3NkBp NYHmNHR1TE2VTx?= NXrsW5Q4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hWC2pcD3u[YdifGm4ZTDLRk0{NTFiY3XscJMhf2m2aDDJR|UxKG:oIEKuN{DPxE1? NHjHe5kyQTN7N{OyNi=>
KBV1 M3zQXWN6fG:2b4jpZ{BCe3OjeR?= M{XLSVczKGh? M2HBNmROW09? M1nYU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHAu\2y7Y3;wdo91\WmwLXX4dJJme3OrbnegT2JXOSClZXzsd{B4cXSqIFnDOVAhd2ZiND6xJO69VQ>? M{fr[lE6Ozl5M{Ky
A375 MVzDfZRwfG:6aXOgRZN{[Xl? MVK3NkBp MoPRSG1UVw>? M2LHS2lEPTB;NT60JO69VQ>? Mn;xNVk3PTR2MEi=
RS4-11 M4rz[2Z2dmO2aX;uJGF{e2G7 NF3Oe44zKGh? MVPJcohq[mm2aX;uJI9nKE[OVEOgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFk6KM7:TR?= MYKxPVY2PDRyOB?=
RS4-11 M{P5dmZ2dmO2aX;uJGF{e2G7 NFrFW|gzKGh? M3zJRWlvcGmkaYTpc44hd2ZiRlzUN{BKXERibYX0ZY51KGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODN2IN88US=> NH[xS5UyQTZ3NESwPC=>
Sf9 M2CwTGtqdmG|ZTDBd5NigQ>? MVGzNEBucW5? M36yfWlvcGmkaYTpc44hd2ZiR2PUMZRi\2enZDDWSWdHWiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFAvOTh3IN88US=> NUfXTGhYOTl6NUSwOVE>
Ba/F3 NEe3SlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHvWN|c4OiCq MUnJR|UxRTFwMjFOwG0> NWDWUoI{OjBzMUewNFQ>
BaPTC2 M13DTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MleyO|IhcA>? M1nSNmlEPTB;MD6yNkDPxE1? NU\Uc|hQOjBzMUewNFQ>
Sf9 NVv5R2h4TnWwY4Tpc44hSXO|YYm= MVuxJIg> NHnaclhFVVOR NI\5XlJKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjpd{11[WepZXSgVmVVKGW6cILld5Nm\CC5aYToJGlEPTBib3[gNU4{KM7:TR?= NVrobFZ6OjBzMUewNFQ>
H4 NHi2cHVEgXSxdH;4bYMhSXO|YYm= MkH1NVAh|ryP MUjUc5hq[2m2eTDpckBpfW2jbjDIOEBk\Wyucx?= NXjFT4tpOjB|NUC4NFY>
SF-539 MXPLbY5ie2ViQYPzZZk> MXuzN|Mh|ryP NU\XRpNQPjBibXnu MnTOSG1UVw>? MkfGTY5pcWKrdHnvckBw\iCSRFfGVoJmfGFicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCxNk4zKM7:TR?= NX\QSVRJOjB2MEO3NFA>
U251 M1PaPWtqdmG|ZTDBd5NigQ>? MYezN|Mh|ryP NEK2ZWQ3OCCvaX6= NV74cHZ1TE2VTx?= MUXJcohq[mm2aX;uJI9nKF[HR1\SNkBxcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDF6Lkmg{txO MXeyNFQxOzdyMB?=
A431 M{j3c2tqdmG|ZTDBd5NigQ>? MXzJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEzNjJizszN M4PaU|IxPTV6MEey
A431 M4PEc2tqdmG|ZTDBd5NigQ>? Ml\iTY5pcWKrdHnvckBw\iCYRVfGVlIh\XiycnXzd4VlKHerdHigTWM2OCCxZjCxPE46KM7:TR?= MX:yNFU2QDB5Mh?=
HepG2 MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXS3NkBp MWHJR|UxRTNwOEGg{txO NHTubYkzODV5MEWyOi=>
Kasumi-1 NV3jPYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7OO3g4OiCq Ml3FTWM2OD1yLkCxOkDPxE1? Mny4NlA2PzB3Mk[=
RS4-11 Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2L0W|czKGh? NHTNdoRKSzVyPUGg{txO Mo\XNlA2PzB3Mk[=
THP1 M3PGdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn2O|IhcA>? NVTOcmZPUUN3ME2wMlUh|ryP M376R|IxPTdyNUK2
Kasumi-1 NEDOVpRHfW6ldHnvckBCe3OjeR?= NUj6T2hVUW6qaXLpeIlwdiCxZjDjMWtqfCCjdYTvdIhwe3Cqb4L5cIF1cW:wIIfpeIghUUN3MDDv[kAxNjBzNTFOwG0> MnL6NlA5OzNyM{m=
A549 NHXH[FZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH\BVZUyPiCq NVnzZXl2SW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsdy=> Ml3vNlE1PTB2NkO=
HL60 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPINVYhcA>? NE\oNVdCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzz M3fDRlIyPDVyNE[z
HUVEC NV7QOVNHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S2bVE3KGh? NEjLRplKdmirYnn0bY9vKG:oIG\FS2YucW6mdXPl[EBk\WyuIIDyc4xq\mW{YYTpc44hf2m2aDDJR|UxKG:oIEKuO|Uh|ryP NIrGbXozOTR3MES2Ny=>
HUVEC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXHNGlHOTZiaB?= MXLJcohq[mm2aX;uJI9nKGKIR1[tbY5lfWOnZDDj[YxtKHC{b3zp[oVz[XSrb36ge4l1cCCLQ{WwJI9nKDRwMESg{txO M36xT|IyPDVyNE[z
IM9 NFvtVo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIrRPVIyPiCq NUW3W3dzSW62aYT1cY9zKGGldHn2bZR6KGGpYXnud5QhcHWvYX6gTW06KGOnbHzz M1\KbVIyPDVyNE[z
K562 M{[yZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUOxOkBp MUTBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6|dDDoeY1idiCNNU[yJINmdGy| NVHQfYhCOjF2NUC0OlM>
MDA-MB-231 NWDPTlB[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIP0dlgyPiCq M2T1O2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3ERU1OSi1{M{GgZ4VtdHN? NV\GNoFCOjF2NUC0OlM>
H460 MomzR5l1d3SxeHnjJGF{e2G7 MUC3NkBp Mm[5TWM2OD1{Lkeg{txO NHv6dnkzOTZ{MUi4NC=>
SMMC7721 MXvDfZRwfG:6aXOgRZN{[Xl? NWe3Tm1sPzJiaB?= M1HyZWlEPTB;Nj60O{DPxE1? NFHFVXAzOTZ{MUi4NC=>
WI38 NV;EcGFRS3m2b4TvfIlkKEG|c3H5 NWrBNmJ5PzJiaB?= MUXJR|UxRThwNU[g{txO MWSyNVYzOTh6MB?=
HEK293 M4PiO2tqdmG|ZTDBd5NigQ>? M1n3bFExOCCwTR?= MXexJIg> NVzmTItQ\G:nczDuc5QhcW6qaXLpeEBXTUeILXnu[JVk\WRiYYX0c5Bpd3OyaH;yfYxifGmxbjDv[kB1gXKxc3nu[UAyOTd3IILld4llfWVib36gWmVITlJ{IHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHN? M4D5PFIyQDh3Mki3
HUVEC Mnv5SpVv[3Srb36gRZN{[Xl? M1PHc|Eh|ryP NGn5R4YzPCCq MkTGRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4hXkWJRj3pcoR2[2WmIHPlcIwhdWmpcnH0bY9v MnK5NlE6PjN|MEW=
HUVEC NXrzcnVRTnWwY4Tpc44hSXO|YYm= Ml3uNUDPxE1? MXGxJIg> M1rxW2lvcGmkaYTpc44hd2ZiRWLLJJBpd3OyaH;yfYxifGmxbjDheEBVcHJ{MEKvWJlzOjB2IHnuJHZGT0Zvc4TpcZVt[XSnZDDIWXZGSw>? MW[yNVk3OzNyNR?=
HUVEC NXLiSFM3TnWwY4Tpc44hSXO|YYm= MUmxJO69VQ>? MVuxJIg> NILrRXhKdmirYnn0bY9vKG:oIHXOU3MheGixc4Doc5J6dGG2aX;uJIF1KFOncj2xNVczKGmwIG\FS2Yue3SrbYXsZZRm\CCKVW\FRy=> M4DmVlIyQTZ|M{C1
HUVEC MVrLbY5ie2ViQYPzZZk> NVHC[YZNOSEQvF2= MoHiNUBp M1[5U2lvcGmkaYTpc44hd2ZiVlXHSnIzKHCqb4PwbI9zgWyjdHnvckBifCC2eYKtNVE4PSCrbjDWSWdHNXO2aX31cIF1\WRiSGXWSWM> MYeyNVk3OzNyNR?=
HUVEC NEPqNlZHfW6ldHnvckBCe3OjeR?= MYGxJO69VQ>? NV3JdllQOSCq Ml20[I9meyCwb4SgbY5pcWKrdDDBT3QheGixc4Doc5J6dGG2aX;uJIF1KFOncj20O|MhcW5iVlXHSk1{fGmvdXzheIVlKEiXVlXD NXvadVFiOjF7NkOzNFU>
HL60 NYj1W4dPS3m2b4TvfIlkKEG|c3H5 NHHwWm82OCEQvF2= NUDDWnNUPDhiaB?= NInETnZFVVOR NInQOIRKSzVyPUG1MlUh|ryP NUT3SZFPOjJyMUmxPFg>
K562 NVjvNWJ5S3m2b4TvfIlkKEG|c3H5 NYO0UFNuPTBizszN MlfMOFghcA>? NHP0ZYxFVVOR NV\IOmVrUUN3ME2yNU46KM7:TR?= MYiyNlAyQTF6OB?=
PC3 MUTDfZRwfG:6aXOgRZN{[Xl? Ml;jOVAh|ryP M2LBW|Q5KGh? MlrZSG1UVw>? NXT0PYNvUUN3ME2yOU4yKM7:TR?= NGjISWwzOjBzOUG4PC=>
SF-539 MWrLbY5ie2ViQYPzZZk> Mn:0N|M{KM7:TR?= MmLPOlAhdWmw NEPuepBKdmirYnn0bY9vKG:oIGDES2ZT[mW2YTD0fZJwe2mwZTDrbY5ie2ViYXP0bZZqfHliaX6gVGRITi2EQj3zeIlufWyjdHXkJIh2dWGwIGPGMVU{QSClZXzsd{B4cXSqIFnDOVAhd2ZiMUKuNkDPxE1? NF;vW2czOjJyNEe0NS=>
HAEC M2r1UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNFAh|ryP NYLudFl4PzJiaB?= NHm3TphCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjBSWMh[2WubIOg[ZhxemW|c3nu[{BXTUeIUjD3bZRpKEmFNUCgc4YhOC5zIN88US=> MUWyNlQ1PDZ5OR?=
HT-29 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUGxNFAh|ryP M1;DRlczKGh? NW\PVmk4SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BmgHC{ZYPzbY5oKF[HR1\SJJdqfGhiSVO1NEBw\iByLkOzJO69VQ>? MnyyNlI1PDR4N{m=
MV4-11 M2T1OmN6fG:2b4jpZ{BCe3OjeR?= MUS3NkBp MXXJR|UxRTBwMECzJO69VQ>? M{LzbVIzPDV{NUG4
HepG2 NVL5SmtYS3m2b4TvfIlkKEG|c3H5 MorEOFghcA>? M4LFUmlEPTB;MUOuNlQh|ryP MUeyNlQ5OzZyOB?=
PC9 NUiwOYRQS3m2b4TvfIlkKEG|c3H5 NFrQNZI1QCCq NWC4fFdNUUN3ME2xNE46PyEQvF2= MW[yNlQ5OzZyOB?=
CAKI-1 NFXXPZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX2xNFAh|ryP M3PxUlQ5KGh? NWTDZYJjTE2VTx?= NGX3Ro5IUTVyPUCuOlMh|ryP MUiyNlU3ODZ{Nx?=
EKVX M1G4WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWexNFAh|ryP MmnwOFghcA>? NVe0TVhsTE2VTx?= MUDHTVUxRTdwOTFOwG0> MlTINlI2PjB4Mke=
MCF7 NETzOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPUSJgyODBizszN NETvVHQ1QCCq M4H4emROW09? MlzFS2k2OT1{IN88US=> MX2yNlU3ODZ{Nx?=
MDA-MB-435 NUHTUYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUexNFAh|ryP M3HGdFQ5KGh? NWDqR|AxTE2VTx?= NH3afXJIUTV{PUKg{txO M2LCeVIzPTZyNkK3
OVCAR3 NV;ZVnZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVOxNFAh|ryP MoXMOFghcA>? NHnaOWZFVVOR NV\WPZY4T0l3M{2zMlIh|ryP NVHnOVREOjJ3NkC2Nlc>
SNB19 NXLZPY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1KwXFExOCEQvF2= M{TxXlQ5KGh? MUPEUXNQ MUfHTVU1RTFyIN88US=> MYiyNlU3ODZ{Nx?=
SW620 NVrMbGRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUmxNFAh|ryP NGHkb3Y1QCCq MX7EUXNQ M3fDVGdKPTV;MT6zJO69VQ>? MUKyNlU3ODZ{Nx?=
TK10 M1TofGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mk\1NVAxKM7:TR?= Ml:wOFghcA>? M1r0NWROW09? NVG2VVByT0l3Nk22MlMh|ryP NXv4bHdVOjJ3NkC2Nlc>
UACC257 Ml;QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXiRYUyODBizszN M{np[FQ5KGh? M4T0SGROW09? MY\HTVU4RTRizszN M2XYcFIzPTZyNkK3
HAEC MlvkR5l1d3SxeHnjJGF{e2G7 M1PUdlExOCEQvF2= MVi3NkBp M1HxfGROW09? M4fD[WN6fG:2b4jpZ4l1gSCjZ3HpcpN1KF[HR1\SJIV5eHKnc4PpcochUEGHQzD3bZRpKEmFNUCgc4YhOC5zIN88US=> NUL3b4tlOjNzM{G1OFE>
HT-29 MnrJR5l1d3SxeHnjJGF{e2G7 M3jQWFExOCEQvF2= NWj2Z4UyPzJiaB?= MlzCSG1UVw>? MlLFR5l1d3SxeHnjbZR6KGGpYXnud5QhXkWJRmKg[ZhxemW|c3nu[{BpfW2jbjDIWE0zQSClZXzsd{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1? Mn3LNlMyOzF3NEG=
HCT116 NUmySWVyTnWwY4Tpc44hSXO|YYm= NYXG[|RVOjRiaB?= MlfuSG1UVw>? MXjBcpRqdWmpcnH0c5J6KGGldHn2bZR6KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4Yh[2WubDDtbYdz[XSrb36= Mm\zNlMyPTN{MEC=
HUVEC MYHGeY5kfGmxbjDBd5NigQ>? NHn2eZEzKM7:TR?= NWrqeG5vOThiaB?= M13UWGROW09? MUjBcpRq[W6paX;n[Y5q[yCjY4Tpeol1gSCrbjDIWXZGS3NidX7k[ZIhcHmyb4jpZ{Bkd26maYTpc44h[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB1fWKnIH\vdo1ifGmxbh?= MYqyN|E2OzJyMB?=
ACHN NUHBUFFwS3m2b4TvfIlkKEG|c3H5 NVXQToM2PiCm MXLJR|UxRTJwNTFOwG0> NELWXIYzOzN4MEGwOC=>
A498 NV7aNJpHS3m2b4TvfIlkKEG|c3H5 M2HONlExOCEQvF2= NIjOTVU4OiCq NXnxXFlvTE2VTx?= M1zHSWlEPTB;ND6zJO69VQ>? M3;MbVI{PDh7NkK2
HUVEC NFGxTFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYGzJO69VQ>? MYGyOEBp NHG2[nVFVVOR MkCwRY51cWGwZ3nv[4VvcWNiYXP0bZZqfHliYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCYRVfGMYlv\HWlZXSgeJVj\SCob4LtZZRqd25id3n0bEBGSzVyIH;mJFAvPjR3IN88US=> NGPLd28zOzV6M{mxNS=>
HUVEC M2i4ZmtqdmG|ZTDBd5NigQ>? NXTG[md5OjByIN88US=> MUDEUXNQ NGW4cmRKdmirYnn0bY9vKG:oIG\FS2ZTOiCyaH;zdIhwenmuYYTpc44hcW5iZ4Lve5RpKG[jY4Tvdk1{fGmvdXzheIVlKEiXVlXD NH\tT3IzOzV6M{mxNS=>
HUVEC MUHLbY5ie2ViQYPzZZk> NGTHdJczODBizszN MmTaSG1UVw>? MVvJcohq[mm2aX;uJI9nKF[HR1\SNUBxcG:|cHjvdplt[XSrb36gbY4h\3Kxd4ToJIZi[3Sxcj3zeIlufWyjdHXkJGhWXkWF NUjUZZB1OjN3OEO5NVE>
A549 NY\RUJd2S3m2b4TvfIlkKEG|c3H5 MlLqO|IhcA>? MUDEUXNQ MoDJTWM2OD1{LkS0JO69VQ>? NH;VSlYzOzZyMkS0NS=>
HCT116 NWS2SJRzS3m2b4TvfIlkKEG|c3H5 MoW3O|IhcA>? MXTEUXNQ MnLDTWM2OD12LkexJO69VQ>? MUCyN|YxOjR2MR?=
MCF7 MYXDfZRwfG:6aXOgRZN{[Xl? NUfp[HdpPzJiaB?= NXSzUXRoTE2VTx?= MXfJR|UxRTZwMkmg{txO NVTjU5dXOjN4MEK0OFE>
BGC Mn7sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUfRWFR5PzJiaB?= MorBSG1UVw>? MkTiTWM2OD12Lke4JO69VQ>? M1KwSlI{QTl7MESw
BxPC3 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXqZZc4OiCq M{T5fGROW09? M4nhOWlEPTB;Mz62N{DPxE1? MVyyN|k6QTB2MB?=
HT-29 Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1j2cFczKGh? NYDCSXJ5TE2VTx?= M1K4TGlEPTB;MT60O{DPxE1? MXuyN|k6QTB2MB?=
T24 NYfQXpF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LzU|czKGh? NHH3PJNFVVOR NVzrVINTUUN3ME2yMlQ1KM7:TR?= NHPiVXczOzl7OUC0NC=>
4T1 M3fuO2N6fG:2b4jpZ{BCe3OjeR?= M1vtNFczKGh? NV3BNZJoTE2VTx?= NWjqN41YUUN3ME2wMlAyPiEQvF2= M4DMUlI1QDlyNkWy
MCF7 NWHBNIZuS3m2b4TvfIlkKEG|c3H5 MXW3NkBp Mn\ZSG1UVw>? MorkTWM2OD1yLkCyO|Eh|ryP MlTWNlQ5QTB4NUK=
MCF7 NWP2TGRXS3m2b4TvfIlkKEG|c3H5 M2jKc|czKGh? MlzGSG1UVw>? MlvpTWM2OD1yLkCyPVMh|ryP MXiyOFg6ODZ3Mh?=
MDA-MB-231 NGn5TllEgXSxdH;4bYMhSXO|YYm= MV63NkBp NYPMNmhXTE2VTx?= MVfJR|UxRTBwMEKyN{DPxE1? NGDPcWszPDh7ME[1Ni=>
MDA-MB-435 MXTDfZRwfG:6aXOgRZN{[Xl? NXm0OlJIPzJiaB?= Mo[5SG1UVw>? MXLJR|UxRTBwMEC5O{DPxE1? MlX1NlQ5QTB4NUK=
MDA-MB-468 NGi3SWREgXSxdH;4bYMhSXO|YYm= NWrJRlRSPzJiaB?= M37T[2ROW09? MUHJR|UxRTBwMEC2NUDPxE1? Mn6zNlQ5QTB4NUK=
A431 NUflWYJuU2mwYYPlJGF{e2G7 MlLpNVAh|ryP M1LTS|EhcA>? NEXHXGRFVVOR Ml3DTY5pcWKrdHnvckBw\iCHR1\SJJdqfGhiSVO1NEBw\iByLkG3NlEh|ryP MkHPNlQ5QTB4NUK=
SH-SY5Y M3uxXGtqdmG|ZTDBd5NigQ>? M1HaZlExKM7:TR?= MWGxJIg> MknVSG1UVw>? MVPJcohq[mm2aX;uJI9nKFCGR1\SZoV1[SC5aYToJGlEPTBib3[gNE4xQDNzIN88US=> NUTJd4N1OjR6OUC2OVI>
U251 M4\PTGtqdmG|ZTDBd5NigQ>? MVKxNEDPxE1? NGjvZVEyKGh? M{PtSGROW09? MWLJcohq[mm2aX;uJI9nKF[HR1\SNkB4cXSqIFnDOVAhd2ZiMD6wNVg6KM7:TR?= MkjmNlQ5QTB4NUK=
Bel7402 NFz0XXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXjN2E1PzJiaB?= MmCwSG1UVw>? NUfqfJJHUUN3ME2yMlY4KM7:TR?= NYTzT41qOjR7MES5OlE>
HK2 M2HhZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3tOlk4OiCq M1ztPGROW09? M{XXTGlEPTB;NT64OUDPxE1? NV7lXJcxOjR7MES5OlE>
LO2 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDxO|IhcA>? MojISG1UVw>? NXf3S|lJUUN3ME2xPU46OyEQvF2= M3GzOFI1QTB2OU[x
MV4-11 M3H6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXq0PEBp M{H2dGROW09? MYHJR|UxRTBwMECzJO69VQ>? NUXPflljOjR7MES5OlE>
NCI-H3122 NXGySYN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYC3NkBp M4DBfWROW09? Mle2TWM2OD1yLkizJO69VQ>? NGDrTXUzPDlyNEm2NS=>
NCI-H460 NUWwOJdHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDoe3lmPzJiaB?= MlToSG1UVw>? MXvJR|UxRTRwM{Gg{txO Mli4NlQ6ODR7NkG=
NCI-H526 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYi3NkBp M2\LXWROW09? NWi1bINIUUN3ME2xMlAyKM7:TR?= Mn7VNlQ6ODR7NkG=
TT M4TUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIfEfVc4OiCq NGPm[IZFVVOR MWDJR|UxRTBwMESg{txO NH32UFAzPDlyNEm2NS=>
EoL-1-cell MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTFwNkSgdG0> Ml3wV2FPT0WU
MV-4-11 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3fhdmlEPTB;MkeyJJBO M1;BSnNCVkeHUh?=
NOS-1 NVfzUHl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17lO2lEPTB;MUWuN{BvVQ>? MkTVV2FPT0WU
CGTH-W-1 MmDnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXubXFKSzVyPUOwMlk1KG6P NHzwcHJUSU6JRWK=
MONO-MAC-6 NGG4NohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPOU5NKSzVyPUOzMlghdk1? M1XmVXNCVkeHUh?=
ALL-PO NGrxTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXXSXNKSzVyPUe5Mlg6KG6P MWrTRW5ITVJ?
NKM-1 NHnFNJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXiTGZKSzVyPUm4MlUzKG6P M1u3OnNCVkeHUh?=
KM12 NXLEWYFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLPUlNKSzVyPUO1NE4yPCCwTR?= MWTTRW5ITVJ?
TE-15 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVLRWWtwUUN3ME21NFcvPjFibl2= MV7TRW5ITVJ?
697 M{L1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nDTGlEPTB;NkG0MlI2KG6P M3j3dnNCVkeHUh?=
MOLT-16 NGjZNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUnHO45CUUN3ME22N|EvOzJibl2= MkHwV2FPT0WU
GB-1 NX63[ZQzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrINHVKSzVyPUexNE4zOyCwTR?= MV7TRW5ITVJ?
TE-12 NI\sN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjrRYVKSzVyPUiwOE42PSCwTR?= NIjad|VUSU6JRWK=
ES6 NH6wfGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DwXWlEPTB;OUixMlA3KG6P MlLhV2FPT0WU
LC-2-ad NGLoboVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTFwMUG0NFch|ryP M13Qb3NCVkeHUh?=
BL-70 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DCS2lEPTB;MT6xNVg1PiEQvF2= MWnTRW5ITVJ?
ETK-1 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWe0TpI6UUN3ME2xMlI5PThizszN M3XwUnNCVkeHUh?=
A4-Fuk MoHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2flfGlEPTB;MT6zOFE1OSEQvF2= MnHMV2FPT0WU
OCI-AML2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\GR5FKSzVyPUGuN|Y5PTFizszN MnnLV2FPT0WU
SIG-M5 NV7leIZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXWOoVKSzVyPUGuN|cxODlizszN NImzd5VUSU6JRWK=
NCI-SNU-16 NXLicm1qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfaTWM2OD1zLkS2OFg3KM7:TR?= NVLkSJB[W0GQR1XS
PSN1 NV;2boh5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFrZSGJKSzVyPUGuOVA3PzZizszN MVfTRW5ITVJ?
SR M4XRWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnToTWM2OD1zLkW0OVczKM7:TR?= NWfndZBGW0GQR1XS
A3-KAW MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NID1RnJKSzVyPUGuOlI2PDZizszN MYfTRW5ITVJ?
KS-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknSTWM2OD1zLk[5NlQ4KM7:TR?= M3PnSnNCVkeHUh?=
CTV-1 MljDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlj3TWM2OD1zLkeyO|UyKM7:TR?= MVPTRW5ITVJ?
LB1047-RCC MojJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlLFTWM2OD1zLkixOlI1KM7:TR?= M2TsUnNCVkeHUh?=
EMG-01 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTFwOEO1OlMh|ryP Mkf0V2FPT0WU
TE-11 Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLvfWRwUUN3ME2xMlg{QTh3IN88US=> MYrTRW5ITVJ?
CMK NEP5[JBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTFwOUW1NVch|ryP MWfTRW5ITVJ?
NB1 MmfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkHvTWM2OD1zLkm2NVE4KM7:TR?= NHr6PFVUSU6JRWK=
HAL-01 MljVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:4ZYhTUUN3ME2yMlA2QTR4IN88US=> MmHQV2FPT0WU
DEL NFHsZZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\KPJdKSzVyPUKuNFg1QDJizszN M3zNTnNCVkeHUh?=
RL95-2 NIrwe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJwMUGxN|ch|ryP NVvqPVFQW0GQR1XS
KARPAS-299 M{LjR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1L2e2lEPTB;Mj6xNVMyOyEQvF2= M4TVc3NCVkeHUh?=
EW-16 M3jCW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;kTWM2OD1{LkGzOVA5KM7:TR?= NVHDV3ZSW0GQR1XS
RS4-11 NH7v[FJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLMTWM2OD1{LkG3PVI1KM7:TR?= NGHkZ2hUSU6JRWK=
BB30-HNC MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFy1UGVKSzVyPUKuNlI{PzVizszN NVnaO3BpW0GQR1XS
DOHH-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTJwM{O0N|Eh|ryP NWfqXIFnW0GQR1XS
RPMI-8402 NIXtVVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrncXpKSzVyPUKuN|M3OThizszN MmTwV2FPT0WU
BV-173 NHrtdGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTJwM{O2OkDPxE1? NXThbopwW0GQR1XS
TE-10 MmG5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvmcW1KSzVyPUKuN|Q{QDRizszN M4\WTXNCVkeHUh?=
TE-8 NF\vd4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7PPJVKSzVyPUKuN|cxOzhizszN NV;seZpXW0GQR1XS
K052 NXe2R4pRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjwRmFsUUN3ME2yMlQxOjB{IN88US=> Mny1V2FPT0WU
KARPAS-45 NWn3[IxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\QT4NqUUN3ME2yMlQ6PDR4IN88US=> MmXVV2FPT0WU
SK-NEP-1 MnmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInHPGRKSzVyPUKuOlAzOzdizszN NVOzSWttW0GQR1XS
KGN NUT2TFdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXLZZWRvUUN3ME2yMlYxOzN7IN88US=> NHTwSnRUSU6JRWK=
ML-2 NUH3VmlNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJwNkO1NVIh|ryP Mor4V2FPT0WU
LAMA-84 MlzyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTJwNkm1OFUh|ryP Mkf3V2FPT0WU
LXF-289 NVjD[VMxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEDVZ5lKSzVyPUKuO|I6QDlizszN NFLPS|lUSU6JRWK=
A101D MnjhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mo\iTWM2OD1{Lke4N|A1KM7:TR?= MUDTRW5ITVJ?
KY821 NWPPO2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonKTWM2OD1{Lke5O|U5KM7:TR?= MmLiV2FPT0WU
ES4 MljiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXy1S5NSUUN3ME2yMlgxPjJ6IN88US=> NVHxdVVCW0GQR1XS
SCC-3 M1PEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\SOGhKSzVyPUKuPFI5QTFizszN M3fFRXNCVkeHUh?=
NALM-6 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTJwOUC0O|Mh|ryP M2q5O3NCVkeHUh?=
BL-41 M3\2cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mkn6TWM2OD1{LkmxNlIzKM7:TR?= NW\jcowyW0GQR1XS
OPM-2 NUfBe5BMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfyU5RKSzVyPUOuNFU6PTRizszN Mln2V2FPT0WU
SF126 NF;scHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwME[xPVgh|ryP MnTjV2FPT0WU
BE-13 NU\6clJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjlOGhRUUN3ME2zMlI{OTFzIN88US=> MU\TRW5ITVJ?
SF268 M4jjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrOR|RmUUN3ME2zMlMzQDZ7IN88US=> MoDxV2FPT0WU
MOLT-4 MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHrTWM2OD1|LkO5PFM5KM7:TR?= MlvJV2FPT0WU
PF-382 MlPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTNwNES1O{DPxE1? NHPvOmhUSU6JRWK=
HEL NHfTN3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUO1XnRlUUN3ME2zMlQ5ODB3IN88US=> NUPaSXgyW0GQR1XS
RPMI-6666 Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{[4OmlEPTB;Mz61OFE4OSEQvF2= MoTiV2FPT0WU
QIMR-WIL MnjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3nTWM2OD1|Lk[zN|kyKM7:TR?= MVHTRW5ITVJ?
ATN-1 NFnGXnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTNwNkexNVQh|ryP NWGwTGp2W0GQR1XS
BB49-HNC MlnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTNwN{C1NFgh|ryP NHjQ[nhUSU6JRWK=
HCE-4 MnjjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTNwN{i2OFIh|ryP NXu2bI5QW0GQR1XS
SK-LMS-1 M3HBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYjJR|UxRTNwOEOzN|gh|ryP NFLWS4pUSU6JRWK=
MS-1 NF7pO4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvNZ3I3UUN3ME2zMlg{Pzd6IN88US=> M4D5UXNCVkeHUh?=
JAR NVPlUJg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkG3TWM2OD1|Lkm4PFMzKM7:TR?= M2q1WHNCVkeHUh?=
KE-37 NEPwUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzne3FKSzVyPUSuNFYyPThizszN MmfTV2FPT0WU
LB996-RCC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlSwTWM2OD12LkGyNVY5KM7:TR?= NIfpUZlUSU6JRWK=
HH M4rvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfKemU{UUN3ME20MlIxQTF2IN88US=> NET0fpNUSU6JRWK=
HL-60 NHTXU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwMkGwOlUh|ryP MnLHV2FPT0WU
HOP-62 NVGzfmVqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLnTWM2OD12LkOzOVIh|ryP NX\ZRY01W0GQR1XS
NOMO-1 NYG5RZZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLObY5KSzVyPUSuN|M3QTlizszN NF7UZ2ZUSU6JRWK=
DU-4475 NXfzUoRbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXTpRYNiUUN3ME20MlM3PzJ7IN88US=> MkTvV2FPT0WU
LC4-1 NWHwemRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHiNHZ7UUN3ME20MlM5ODdizszN Ml3VV2FPT0WU
MC116 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTRwNEOwPFEh|ryP M{jMPHNCVkeHUh?=
SW982 MmjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWPJTIdVUUN3ME20MlU2OzB5IN88US=> MlGwV2FPT0WU
SK-N-DZ M1\xS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX3TWM2OD12Lk[3NFk6KM7:TR?= MnHOV2FPT0WU
EW-1 M1y0V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLWfVNsUUN3ME20MlY4QTFzIN88US=> MUHTRW5ITVJ?
SU-DHL-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDncFZHUUN3ME20MlgxOTd2IN88US=> Ml\nV2FPT0WU
L-363 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHUeoJKSzVyPUSuPFA3OjFizszN MXrTRW5ITVJ?
OS-RC-2 NFG3T2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnnTWM2OD12Lki3N|Eh|ryP NHHKeXZUSU6JRWK=
HD-MY-Z NXzXTnZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETpUpZKSzVyPUWuNVc{ODFizszN MVLTRW5ITVJ?
MHH-PREB-1 NEPucHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPCTZhZUUN3ME21MlMzOzF{IN88US=> NWjTU5RLW0GQR1XS
HC-1 M2PKUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTVwNEOyPVEh|ryP NXXKbmNqW0GQR1XS
SK-MM-2 NH;1Vo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEewSoFKSzVyPUWuOFc5OiEQvF2= MWPTRW5ITVJ?
SH-4 MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVeyeYlsUUN3ME21MlQ5OzdizszN NWrWSWRoW0GQR1XS
MHH-CALL-2 M2W3N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXiS2xKSzVyPUWuO|Y4OTlizszN NGHiRotUSU6JRWK=
KG-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTZwMEK4O|gh|ryP NWHTZ2I{W0GQR1XS
J-RT3-T3-5 NETFVItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{H5TGlEPTB;Nj6wO|kxQSEQvF2= M3K4SHNCVkeHUh?=
MMAC-SF NHzKcY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTZwMUC5OFkh|ryP NVXufmliW0GQR1XS
IST-SL2 M2HiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXWzV5EzUUN3ME22MlEzPTF7IN88US=> M4TzVXNCVkeHUh?=
SW954 NWTCfmxwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLafGhKSzVyPU[uNlc2OTdizszN MUDTRW5ITVJ?
HDLM-2 NILJU2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2PFOmlEPTB;Nj6zNlExQSEQvF2= NFPNUGxUSU6JRWK=
ST486 NYHafnMyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV7H[VcxUUN3ME22MlM1PzFizszN Ml\NV2FPT0WU
DG-75 M3riUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLxWlJrUUN3ME22MlQ{ODZ7IN88US=> Mm\kV2FPT0WU
EW-3 Mn;WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVSwVVhQUUN3ME22MlQ{OjB5IN88US=> MmDzV2FPT0WU
8-MG-BA MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDGTHRKSzVyPU[uOVE2ODdizszN M2fFNXNCVkeHUh?=
GT3TKB NYDDeYhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HvZWlEPTB;Nj62NFc3OyEQvF2= M{POc3NCVkeHUh?=
KU812 NFm2fYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mme2TWM2OD14Lk[5OFIh|ryP M2\YdnNCVkeHUh?=
CESS NYO1UGFJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rRbWlEPTB;Nz6xNFQ{QCEQvF2= M{\HdXNCVkeHUh?=
BC-1 MkSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFzrW2RKSzVyPUeuNlQ5OTJizszN M3LvfnNCVkeHUh?=
MZ1-PC Ml;mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7ZZYxnUUN3ME23MlMxOzh7IN88US=> MlzzV2FPT0WU
NCI-H82 M{XxZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mmf5TWM2OD15LkO3PFUh|ryP MXTTRW5ITVJ?
NCI-H1355 M2XySWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPtdHBzUUN3ME23MlQ2QDB2IN88US=> NWPENGVuW0GQR1XS
RPMI-8226 MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fVW2lEPTB;Nz61NFc{QSEQvF2= MWrTRW5ITVJ?
ARH-77 M3\sUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK5Z5NKSzVyPUeuOVM2QTdizszN MX;TRW5ITVJ?
MN-60 Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXJeVhlUUN3ME23MlU1ODh6IN88US=> MUTTRW5ITVJ?
IMR-5 M2\6cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1izbmlEPTB;N{C1OFg4PiEQvF2= NXrl[WRyW0GQR1XS
KARPAS-422 M37j[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nLd2lEPTB;Nz61O|IxPiEQvF2= Mm[zV2FPT0WU
CA46 M2DlU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mnn1TWM2OD15LkW4NFEzKM7:TR?= MYfTRW5ITVJ?
SJSA-1 MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TmN2lEPTB;Nz62OlA3OSEQvF2= M1WwTXNCVkeHUh?=
no-11 Mo[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTdwN{e1OVch|ryP NWPjXG9YW0GQR1XS
IST-SL1 NEj3TXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13hUGlEPTB;OD6wNlQyPyEQvF2= NYK5SIRoW0GQR1XS
NCI-H209 NXHlcGlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVexVGJUUUN3ME24MlEyPjV{IN88US=> MVPTRW5ITVJ?
TALL-1 NGrITJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDFfHRKSzVyPUiuNVg{QDRizszN MUDTRW5ITVJ?
KMOE-2 MoH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELi[HRKSzVyPUiuNVk1OiEQvF2= MlPlV2FPT0WU
HCC1599 M1foNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DkUGlEPTB;OD6xPVk5PyEQvF2= NYK5dYRXW0GQR1XS
CI-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRThwMkC0NVEh|ryP MVPTRW5ITVJ?
NCI-H1304 NX;ufXJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{S5eWlEPTB;OD6yNFY3OSEQvF2= M1W2XHNCVkeHUh?=
Daudi NIDseWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnrITWM2OD16LkKzOVQ3KM7:TR?= MXvTRW5ITVJ?
CPC-N NW\lWnlVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDuVHBKSzVyPUiuNlkyQTlizszN MXTTRW5ITVJ?
MC-CAR MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm0c3hCUUN3ME24MlM{PThizszN NG\1RnVUSU6JRWK=
SW872 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLV[2tPUUN3ME24MlM1PzV6IN88US=> NYG3eWt{W0GQR1XS
OVCAR-4 NHKycpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXDeGlKSzVyPUiuOVA{PTFizszN NGC5d|NUSU6JRWK=
OCUB-M NGXSOGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFT0SmNKSzVyPUiuOVY2ODhizszN NXftZlZ3W0GQR1XS
SK-PN-DW M{nIPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRThwNkC5PFUh|ryP NIn1dXFUSU6JRWK=
NCCIT MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFWxZnpKSzVyPUiuO|E4PDVizszN MYHTRW5ITVJ?
NCI-H1648 M{f3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTlwMUO4N|Qh|ryP NHTKdm9USU6JRWK=
COR-L279 NV\zbYZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUm2XZh3UUN3ME25MlM6ODlizszN NFTve5hUSU6JRWK=
LS-123 NG\jTWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{THeGlEPTB;OT62PFE3OSEQvF2= NVy4PJJGW0GQR1XS
LP-1 MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHy1Z3pKSzVyPUmuO|gxQDNizszN NVLUN45qW0GQR1XS
NB13 M4jue2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;xTWM2OD17Lke5PVk1KM7:TR?= MnfpV2FPT0WU
ONS-76 M{D0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LBbWlEPTB;OT64NVAyPiEQvF2= NEXafGJUSU6JRWK=
VA-ES-BJ MluwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zCemlEPTB;OT65PVk{OyEQvF2= MUPTRW5ITVJ?
GR-ST NImwOFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnKNYVzUUN3ME2xNE4zOjB5IN88US=> NW\qT3VyW0GQR1XS
ES1 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXveotKSzVyPUGwMlI6QDRizszN M4[1N3NCVkeHUh?=
NB14 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3LdpVKSzVyPUGwMlkzPzdizszN NHnDNHpUSU6JRWK=
Ramos-2G6-4C10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL2TWM2OD1zMT6yOlUh|ryP M4P4TXNCVkeHUh?=
RXF393 Mn;4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFzLkS4N|Qh|ryP NXvk[4dWW0GQR1XS
NCI-H2107 M{nJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4j5N2lEPTB;MUGuOVk5PCEQvF2= MnnIV2FPT0WU
K562 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVz3XlR3UUN3ME2xNU45PzB{IN88US=> NFPKdpBUSU6JRWK=
LOUCY M4PLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGH4SJZKSzVyPUGxMlk5PzVizszN NEm5UZFUSU6JRWK=
TGBC1TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVvM[m9WUUN3ME2xNk4xODJizszN M2PoWHNCVkeHUh?=
COLO-320-HSR NGjWSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37EfmlEPTB;MUKuNVU3PSEQvF2= M1XnNXNCVkeHUh?=
K5 NX:xXGVLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX65OZNLUUN3ME2xNk4zQTh3IN88US=> NXezU2p3W0GQR1XS
BC-3 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPINZdTUUN3ME2xNk41PjVzIN88US=> MmKxV2FPT0WU
REH NE\EXGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF71WHlKSzVyPUGyMlY1QThizszN MnHNV2FPT0WU
NEC8 NF;jdoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnncVNKSzVyPUGyMlY5QDdizszN NYTOfY5TW0GQR1XS
IST-MEL1 NXz4W4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\VRpNKSzVyPUGyMlg3QTRizszN MV3TRW5ITVJ?
NCI-H128 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYS2OopbUUN3ME2xN{4xPzJ|IN88US=> NVP2blBsW0GQR1XS
NCI-H1694 NHW4SnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDYZldKSzVyPUGzMlEyPDRizszN MkPmV2FPT0WU
TGW NW\QdpBiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[we4NKSzVyPUGzMlMzPzZizszN Mlj5V2FPT0WU
NCI-SNU-1 MnfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnv6TWM2OD1zMz6zOFUh|ryP MkHxV2FPT0WU
IST-MES1 M4THcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmfZTWM2OD1zMz62O|I6KM7:TR?= MlHWV2FPT0WU
CTB-1 NXrDTos1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITyNo1KSzVyPUGzMlczQTRizszN NG\T[ZpUSU6JRWK=
HUTU-80 NF3mS5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYm3c2lnUUN3ME2xN{44PTd|IN88US=> NFnrPIJUSU6JRWK=
LAN-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVnhV2NmUUN3ME2xOE4zPDV5IN88US=> MUDTRW5ITVJ?
KP-N-YS Mli4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M336dGlEPTB;MUSuNlg6PCEQvF2= MWTTRW5ITVJ?
CCRF-CEM NFnJXmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1LLV2lEPTB;MUSuOFE3QSEQvF2= MlnlV2FPT0WU
NCI-H1770 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrJfopKSzVyPUG0MlU{PjlizszN M3TLRXNCVkeHUh?=
MZ2-MEL MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPHeG4xUUN3ME2xOU4zOjVzIN88US=> NWnNWG82W0GQR1XS
COR-L88 M3rwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPQTWM2OD1zNj6wNFEzKM7:TR?= NWX1XoNKW0GQR1XS
LOXIMVI Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYXJR|UxRTF4LkK1OkDPxE1? M1fiSXNCVkeHUh?=
KALS-1 NGfoUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MojvTWM2OD1zNj61PVMyKM7:TR?= MnWyV2FPT0WU
D-283MED NXrqdYxxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXuO4ZKSzVyPUG2Mlg1QDlizszN M{GyVHNCVkeHUh?=
NCI-H719 NYW2do1ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjpb2FZUUN3ME2xOk46OTZzIN88US=> Mk[1V2FPT0WU
MLMA Mnv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrWPJJZUUN3ME2xOk46QTB5IN88US=> NUK3NmJWW0GQR1XS
EVSA-T MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLhcGVNUUN3ME2xO{4xPDh3IN88US=> NUXhSJY6W0GQR1XS
SK-N-FI NX\lNGh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXW4c282UUN3ME2xO{43QTF|IN88US=> M3rDOXNCVkeHUh?=
NTERA-S-cl-D1 NWHLVpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFTETIpKSzVyPUG3Mlg2PzJizszN NYPIPXloW0GQR1XS
NCI-H1882 M1\6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XmXGlEPTB;MUeuPVg{PCEQvF2= MY\TRW5ITVJ?
A704 MnjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnlWm1KSzVyPUG3Mlk6ODRizszN NFXoXWRUSU6JRWK=
L-428 M{XMeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjlWWhKSzVyPUG4MlAyPTFizszN NGHPU3VUSU6JRWK=
HCC1187 MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTF6LkCxPFch|ryP NIDpe2lUSU6JRWK=
NCI-H1581 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfZTWM2OD1zOD6wPFY3KM7:TR?= Mli3V2FPT0WU
BB65-RCC M4rTd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjTbHBKSzVyPUG4MlQyPjJizszN MXfTRW5ITVJ?
EM-2 NF7ZcIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3ixVGlEPTB;MUiuOVY4OiEQvF2= M4TB[nNCVkeHUh?=
Raji M1S4Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluxTWM2OD1zOT65OVY2KM7:TR?= NGL1[VNUSU6JRWK=
TE-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFS2OZRKSzVyPUKwMlQyODRizszN NXjOVXlUW0GQR1XS
SW962 MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnvMTWM2OD1{MD60Nlk{KM7:TR?= Ml3OV2FPT0WU
MHH-NB-11 NHfUTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHrbW81UUN3ME2yNE42PTJzIN88US=> NGDLN2NUSU6JRWK=
no-10 M2rafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;iTWM2OD1{MT6wNlY1KM7:TR?= M{PtPXNCVkeHUh?=
GDM-1 NEH4So9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzHTWM2OD1{MT65OFE1KM7:TR?= MmrxV2FPT0WU
KMS-12-PE NX\WbGY6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUHNWVBjUUN3ME2yNk4zPzRizszN MlnaV2FPT0WU
NCI-H510A Mnz3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfYTWM2OD1{ND6xNlc5KM7:TR?= NHjTU4pUSU6JRWK=
ES5 NIfre5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7wbZNKSzVyPUK0Mlc{PDlizszN MXPTRW5ITVJ?
JiyoyeP-2003 NIK5SXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2S4NGlEPTB;Mk[uNlc1OiEQvF2= MV3TRW5ITVJ?
NMC-G1 NYLZe3c{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLGUXVMUUN3ME2yO{4yQDJ{IN88US=> M2\jUnNCVkeHUh?=
NCI-H446 MnPnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTJ5LkS5OFYh|ryP M4HETXNCVkeHUh?=
NB7 NYq0XpR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrMd|lKSzVyPUK3MlkzOjlizszN NGHiZVZUSU6JRWK=
A388 NFq4Wo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DnWWlEPTB;MkiuNFA4PCEQvF2= M3;i[HNCVkeHUh?=
JVM-2 MmLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJ6LkK4PVgh|ryP MlrFV2FPT0WU
HT-144 Mm\XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJ6Lk[5JO69VQ>? NF\Xc2pUSU6JRWK=
NCI-H747 Mk\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1:4R2lEPTB;MkiuPVE6PSEQvF2= M{DxO3NCVkeHUh?=
NCI-H1650 NWjnb4s{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK5NlJKSzVyPUK5MlAyPzZizszN MoXwV2FPT0WU
EB-3 Mn\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXTlXVlnUUN3ME2yPU42OzB7IN88US=> MYPTRW5ITVJ?
KLE NUT3dII5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mor4TWM2OD1{OT62NVkh|ryP MYrTRW5ITVJ?
TK10 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTUd|JLUUN3ME2zNE4yOjZizszN MW\TRW5ITVJ?
COLO-668 NYD4XZhIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTNyLke5NkDPxE1? M1frZXNCVkeHUh?=
NCI-H23 M1jH[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYH1e2VPUUN3ME2zNU4yODZ|IN88US=> NGi3dnpUSU6JRWK=
GOTO MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV7JR|UxRTNzLk[wPFUh|ryP M4PYW3NCVkeHUh?=
MSTO-211H MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;sTWM2OD1|MT64Olc5KM7:TR?= NFiyWYVUSU6JRWK=
LB831-BLC M2TUUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jGS2lEPTB;M{KuN|g1OyEQvF2= M2jtcHNCVkeHUh?=
SCH MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTj[m46UUN3ME2zNk45PDh3IN88US=> MWnTRW5ITVJ?
EHEB NWTre5RrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3Ub4xLUUN3ME2zOE4yOTl|IN88US=> MnH2V2FPT0WU
U-266 MmTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDLWFVKUUN3ME2zOE4zPzhzIN88US=> NE\0N2JUSU6JRWK=
EW-11 M{O4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPsTWM2OD1|ND60O|I2KM7:TR?= MkmwV2FPT0WU
TE-9 NIHqVJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYTJR|UxRTN5LkC0NFEh|ryP NGHCNXFUSU6JRWK=
ES3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{PqXGlEPTB;M{euOVAxPCEQvF2= NHXleYdUSU6JRWK=
NCI-H2141 NUTjR|h4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rVZmlEPTB;M{iuNFg1OyEQvF2= M3TMO3NCVkeHUh?=
MPP-89 Mki5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXPTWM2OD12Mj6wOVg3KM7:TR?= NIrISmtUSU6JRWK=
SK-MEL-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\COGdLUUN3ME20Nk43PDB3IN88US=> MV\TRW5ITVJ?
LC-1F MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1GzT2lEPTB;NEOuN|Y5OiEQvF2= MlPQV2FPT0WU
NH-12 NFnNRoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTR|LkmzOVkh|ryP NUTJfY5vW0GQR1XS
RKO MkLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUTJNoZDUUN3ME20OE4yOjV{IN88US=> NVz2VmZ5W0GQR1XS
KM-H2 M1;afmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXjTHRMUUN3ME20OE46PTd5IN88US=> NGTU[5NUSU6JRWK=
SK-UT-1 NGC5bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj1UGRKSzVyPUS5Mlg5OjVizszN M1LYUHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT / AKT / p-ERK / ERK; 

PubMed: 24759734     


Effect of 72 h treatment with sunitinib on SH-SY5Y, SK N BE(2), SK-N-AS and IMR-32 NB cell lines analyzed by Western blot with pSer473Akt, Akt, pThr202/Thr204 Erk1/2 and Erk1/2 antibodies. β-actin was used as a loading control.

p-GSK3β / GSK3β / MYCN ; 

PubMed: 24759734     


Effect of sunitinib on GSK3β phosphorylation and on MYCN total protein in MYCN amplified NB cell lines.

p-STAT3 / STAT3 / p-Src / Src / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 19244102     


Sunitinib reduced Stat3 and Src activity, with no dramatic reduction of AKT, MAPK and JAK signaling in 786-O cells. Tumor cells were treated with sunitinib at indicated concentrations for 2 h (left panels) or 24 h (right panels). Total cell lysates were prepared and western blots were performed using relevant antibodies to detect total protein levels, with β-actin used as the loading control.

24759734 19244102
Growth inhibition assay
Cell viability; 

PubMed: 24369536     


Isolated effects of sunitinib malate on urinary bladder-cancer cell lines viability, assessed by using the MTT assay. The data shown and bars represent the mean values ± SD (SD: standard deviation). *P < 0.05 versus untreated cells.

24369536
In vivo Consistent with the substantial and selective inhibition of VEGFR2 or PDGFR phosphorylation and signaling in vivo, Sunitinib (20-80 mg/kg/day) exhibits broad and potent dose-dependent anti-tumor activity against a variety of tumor xenograft models including HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435. Sunitinib dosing at 80 mg/kg/day for 21 days leads to complete tumor regression in six of eight mice, without tumor re-growing during a 110-day observation period after the end of treatment. Second round of treatment with Sunitinib remains efficacious against tumors that are not fully regressed during the first round of treatment. Sunitinib treatment results in significant decrease in tumor MVD, with ~40% reduction in SF763T glioma tumors. SU11248 treatment results in a complete inhibition of additional tumor growth of luciferase-expressing PC-3M xenografts, despite no reduction in tumor size. [2] Sunitinib treatment (20 mg/kg/day) dramatically suppresses the growth subcutaneous MV4;11 (FLT3-ITD) xenografts and prolongs survival in the FLT3-ITD bone marrow engraftment model. [3]

Protocol

Kinase Assay:[1]
- Collapse

Biochemical Tyrosine Kinase Assays:

IC50 values for Sunitinib against VEGFR2 (Flk-1) and PDGFRβ are determined using glutathione S-transferasefusion proteins containing the complete cytoplasmic domain of the RTK. Biochemical tyrosine kinase assays to quantitate the trans-phosphorylation activity of VEGFR2 (Flk-1) and PDGFRβ are performed in 96-well microtiter plates precoated (20 μg/well in PBS; incubated overnight at 4 °C) with the peptide substrate poly-Glu,Tyr (4:1). Excess protein binding sites are blocked with the addition of 1-5% (w/v) BSA in PBS. Purified GST-fusion proteins are produced in baculovirus-infected insect cells. GST-VEGFR2 and GST-PDGFRβ are then added to the microtiter wells in 2 × concentration kinase dilution buffer consisting of 100 mM HEPES, 50 mM NaCl, 40 μM NaVO4, and 0.02% (w/v) BSA. The final enzyme concentration for GST-VEGFR2 or GST-PDGFRβ is 50 ng/mL. Twenty-five μL of diluted Sunitinib are subsequently added to each reaction well to produce a range of inhibitor concentrations appropriate for each enzyme. The kinase reaction is initiated by the addition of different concentrations of ATP in a solution of MnCl2 so that the final ATP concentrations spanned the Km for the enzyme, and the final concentration of MnCl2 is 10 mM. The plates are incubated for 5-15 minutes at room temperature before stopping the reaction with the addition of EDTA. The plates are then washed three times with TBST. Rabbit polyclonal antiphosphotyrosine antisera are added to the wells at a 1:10,000 dilution in TBST containing 0.5% (w/v) BSA, 0.025% (w/v) nonfat dry milk, and 100 μM NaVO4 and incubated for 1 hour at 37 °C. The plates are then washed three times with TBST, followed by the addition of goat antirabbit antisera conjugated with horseradish peroxidase (1:10,000 dilution in TBST). The plates are incubated for 1 hour at 37 °C and then washed three times with TBST. The amount of phosphotyrosine in each well is quantitated after the addition of 2,2′-azino-di-[3-ethylbenzthiazoline sulfonate] as substrate.
Cell Research:[3]
- Collapse
  • Cell lines: RS4;11, MV4;11, and OC1-AML5
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 24 and 48 hours
  • Method: Cells are starved overnight in medium containing 0.1% FBS prior to addition of Sunitinib and FL (50 ng/mL; FLT3-WT cells only). Proliferation is measured after 48 hours of culture using the Alamar Blue assay or trypan blue cell viability assays. Apoptosis is measured 24 hours after Sunitinib addition by Western blotting to detect cleavage of poly (ADP-ribose) polymerase (PARP) or levels of caspase-3.
    (Only for Reference)
Animal Research:[2]
- Collapse
  • Animal Models: Female nu/nu mice implanted s.c. with HT-29, A431, Colo205, H-460, SF763T, C6, A375, or MDA-MB-435, and male nu/nu mice bearing luciferase-expressing PC-3M tumors
  • Formulation: Formulated as a carboxymethyl cellulose suspension or as a citrate buffered (pH 3.5) solution
  • Dosages: ~80 mg/kg
  • Administration: Orally once daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 15 mg/mL (28.16 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 532.56
Formula

C22H27FN4O2.C4H6O5

CAS No. 341031-54-7
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT01391962 Recruiting Drug: Cediranib|Drug: Sunitinib Sarcoma Alveolar Soft Part National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 19 2011 Phase 2
NCT01073644 Terminated Drug: Sunitinib malate Metastatic Renal Cell Carcinoma Pfizer February 2010 --
NCT00912912 Terminated Drug: Sunitinib Malate Genitourinary Disease M.D. Anderson Cancer Center|Pfizer May 2009 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I was wondering that the compound is in its cis or trans form?

  • Answer:

    S1042 Sunitinib Malate is Z form.

  • Question 2:

    What is the difference between Sunitinib Malate(S1042) and Sunitinib(S7781)?

  • Answer:

    S1042 is the Malate salt form of Sunitinib. The biological activities of these two compounds are the same but the solubility of these two compounds in aqueous solvent are different.

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Sunitinib Malate | Sunitinib Malate supplier | purchase Sunitinib Malate | Sunitinib Malate cost | Sunitinib Malate manufacturer | order Sunitinib Malate | Sunitinib Malate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID